Will reducing inflammation reduce the severe complications from COVID-19?

Bookmark this
22 April, 2020 By Victoria Salas

 


Will reducing inflammation reduce the severe complications from COVID-19?

That’s what one contactless study aims to answer.

 

A phase III randomized double-blind placebo-controlled clinical trial investigating colchicine is underway in Canada and the United States. Colchicine is an anti-inflammatory medication commonly prescribed for Gout.

 

According to UCSF.edu the study has a unique preventative and contactless design. It is being conducted in an outpatient setting specifically for patients that have not yet been hospitalized. Patients must have received a diagnosis of COVID-19 within the last 24 hours and possess at least one high risk criteria (in addition to meeting other inclusion/exclusion criteria you can find on clinicaltrials.gov).

 

The clinical trial is known as the COLCORONA study and is being led by the Montreal Heart Institute. It is currently being conducted in the US at UCSF-San Francisco General Hospital and New York University School of Medicine.

 

Severe complications of COVID-19 may be caused by an inflammatory cytokine storm that produces a major overreaction immune response. The anti-inflammatory effects of colchicine may reduce this reaction that can lead to heart, kidney and other organ damage.

 

A study published in the New England Journal of Medicine in December 2019 concluded that Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo.

 

The study aims to enroll 6000 patients with an estimated completion date in September 2020.

Written by

Victoria Salas